Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20105 in Advanced Solid Tumors
NCT06144723Phase 2Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of HS-20105 in solid tumor, sponsored by Hansoh Pharmaceutical Group. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
HS-20105
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06144723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144723.